New Opportunities in Treatment of Bronchial Asthma
It is not a secret that in Russia high-efficiency foreign drugs are unavailable to the majority of patients with bronchial asthma. As a consequence, it results in lack of control over disease symptoms. One of the ways to solve this is to create domestic analogues for high-cost foreign drugs. Since 2016 a new domestic drug containing a combination of inhaled corticosteroid and long-acting beta-2-agonist (formoterol/budesonide) Formisonid®-nativ appeared on Russian pharmaceutical market. There was performed a multi-center study aimed at conducting a comparative assessment on efficacy and safety for Formisonid<sup>®</sup>-nativ (9 mcg formoterol + 320 mcg budesonide per dose) (LLC Nativa, Russia) and its foreign analogue Symbicort<sup>®</sup> Turbuhaler<sup>®</sup> (9 mcg formoterol + 320 mcg budesonide per dose) (AstraZeneca AB, Sweden). It was shown that efficacy and safety profile for Formisonid<sup>®</sup>-nativ were similar to those of Symbicort<sup>®</sup> Turbuhaler<sup>®</sup>.